KODK

Analyst Note: Eastman Kodak Company (KODK)

Date: 2026-06-13 Current Price: $9.40

1. Structural Readiness

• Conservative Entry: — (Not yet triggered; requires a confirmed breakout above the consolidation ceiling).
• Aggressive/Pre-Breakout Entry: — (Not actionable as a standalone setup; requires confirmation).
• Breakout Level: — (Not yet established; requires price to close above the consolidation range).
• Current Price: $9.40.
• Extension: — (No extension data provided; price is within the consolidation range).
• ATR Context: Current ATR is 5.4% (High). This indicates elevated volatility, which is a key input for position sizing but does not alter the structural state of the coil.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Analysis: As of 2026-06-13, there is no named secular thesis attached to KODK. The investment case is not driven by a macro theme (e.g., "AI Infrastructure" or "Green Energy Transition") but is strictly a function of the technical setup quality combined with the fundamental business performance recorded in the most recent earnings.
• Conviction Weighting: Conviction must be derived entirely from the quality of the forming coil structure and the strength of the Q1 2026 operational metrics. Do not invent a macro narrative; judge the name on its ability to execute its current business model and the structural probability of a breakout from the current consolidation.

3. Business Fundamentals (As of 2026-06-13)

Eastman Kodak Company operates as a global manufacturer focused on commercial print and advanced materials and chemicals. The business model relies on a dual-segment structure supported by hardware, software, consumables, and IP licensing.

• Segment Performance (Q1 2026):
• Revenue Growth: Consolidated revenue increased 7% year-over-year to $265 million (up from $247 million in Q1 2025). Revenue growth was broad-based, increasing in both the Print and Advanced Materials & Chemicals (AM&C) segments.
• Profitability: Gross profit percentage expanded to 22%, a 3 percentage point (16%) increase compared to Q1 2025. Operational EBITDA improved significantly to $15 million, up $13 million from $2 million in the prior year quarter.
• Trend: This marks the third consecutive quarter of year-over-year growth for these key measures.
• Business Lines:
• Print Segment: Comprises Prepress Solutions, PROSPER business, Software, and Electrophotographic Printing Solutions. It serves commercial print, direct mail, book publishing, newspapers, magazines, and packaging/labels.
• AM&C Segment: Comprises Industrial Film and Chemicals, Motion Picture, Pharmaceuticals, Advanced Materials, and IP Licensing.
• *Industrial Film & Chemicals:* Accounted for 23% of total net revenue in 2025 (up from 21% in 2024 and 18% in 2023), indicating a growing reliance on this high-margin or high-volume segment.
• *Motion Picture:* Revenues increased by 9% despite difficult market conditions. Key drivers include the use of Kodak film in major productions such as *Euphoria Season 3* (featuring new film VERITA 200D), *One Battle After Another*, *Sinners*, and the anticipated *The Odyssey* by Christopher Nolan.
• *Pharmaceuticals/Healthcare:* Kodak completed construction of its cGMP lab and manufacturing facility at Eastman Business Park (EBP) in 2025. The facility is certified to manufacture reagents and began producing phosphate buffered saline (PBS) for laboratory use in the second half of 2025.
• Financial Obligations:
• A Term Loan Amendment requires the Company to prepay an aggregate $50 million principal amount of Term Loans by March 18, 2026, and an additional $50 million by June 1, 2026, plus a 1% prepayment premium. (Note: As of June 13, 2026, the March 18 payment is due/past due, and the June 1 payment is due/past due; the company's ability to meet these obligations is a critical operational metric).

4. Archetype and Conviction Stack

• Archetype: Margin Inflector / Deep Value Recovery.
• *Rationale:* The company is demonstrating a clear shift from low-margin legacy operations to higher-margin industrial and specialized chemical applications (cGMP, Industrial Film). The 16% expansion in gross profit percentage and the 750%+ increase in Operational EBITDA ($2M to $15M) signal a successful margin inflection. The business is not a "growth leader" in the traditional sense but is recovering from a distressed state through operational efficiency and strategic pivots (e.g., the cGMP facility).
• Valuation Context:
• Forward Consensus EPS (FY1): $0.00 (Financial spine coverage is 'partial').
• *Implication:* The market currently does not price in positive earnings for the full year 2026, suggesting the Q1 2026 profitability is viewed as a turnaround signal rather than a normalized run-rate. This creates a potential rerating opportunity if the Q1 trend sustains through the full year.
• Conviction Stack:
• Thesis Strength: Low (No macro thesis; purely tactical).
• Evidence Quality: High (Strong Q1 2026 operational data, clear margin expansion, specific product wins in film).
• Structural Quality: Moderate (ATR of 5.4% is in the "High" bucket, indicating volatility risk, but the forming coil structure is intact).
• Setup Readiness: Partial (Forming coil; requires breakout confirmation).
• Rerating Potential: Moderate (Dependent on sustaining the Q1 EBITDA growth and clearing debt obligations).

5. Invalidations, Strengths, and Gaps

• What Would Invalidate the Case:
• Failure to meet the $50 million term loan prepayment obligations (due June 1, 2026), which could trigger covenant breaches or liquidity crises.
• What Would Strengthen the Case:
• A confirmed breakout above the consolidation ceiling (price action clearing the range).
• Continued sequential growth in the AM&C segment, particularly the Industrial Film and Chemicals business (currently 23% of revenue).
• Confirmation of sustained profitability in subsequent quarters (Q2 2026).
• Gaps in Evidence:
• Full Year Guidance: No specific forward guidance for FY2026 revenue or EPS is provided in the evidence base, only the consensus of $0.00.
• Debt Service Coverage: While the prepayment obligation is noted, there is no explicit evidence of the company's *current* cash position or ability to service the debt *after* the June 1 payment in the provided filings.
• Q2 2026 Data: As of June 13, 2026, Q2 2026 results are not yet available; the analysis relies entirely on Q1 2026 data.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Q1 2026 revenue up 7% to $265M with gross margin expansion to 22%; Operational EBITDA surged to $15M (up $13M YoY); Third consecutive quarter of YoY growth; AM&C segment (Industrial Film) now 23% of total revenue. Key risks: Forward consensus EPS is $0.00 indicating market skepticism on full-year profitability; High ATR (5.4%) suggests elevated volatility and potential for false breakouts; Significant debt prepayment obligations ($50M due June 1, 2026) create liquidity pressure; No named secular thesis to support multiple expansion. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state and high volatility; treat as a partial allocation pending confirmation. Expected path: Management expectations indicate continued focus on operational efficiency and cGMP facility utilization; if the company clears the June debt obligation and sustains Q1 margins, the stock may attempt to break out of the current consolidation range. Expected horizon: 3 to 6 months (timeframe for Q2 earnings release and potential breakout confirmation).